Regeneron Reports (PHOTON) and (PULSAR) Study Results of Aflibercept for Diabetic Macular Edema and Wet Age-Related Macular Degeneration
Shots:
- The (PHOTON) & (PULSAR) study evaluates aflibercept (8mg, q12w or q16w) vs Eylea (q8w) in patients with DME & wAMD. Aflibercept is being jointly developed by Regeneron & Bayer
- Both the trial met their 1EPs i.e., patients treated with aflibercept (8mg, 12 & 16wk.) in DME & wAMD achieved non-inferiority in vision gains, and the safety results were consistent with the safety profile of Eylea from a prior clinical trial
- 91% vs 89% of patients with DME & 79% vs 77% in wAMD were rapidly initiated & maintained on 12 & 16wk. dosing intervals through 48wk., no new safety signals & no cases of retinal vasculitis, occlusive retinitis, or endophthalmitis were observed. Regeneron & Bayer will submit the results to regulatory authorities in countries globally
Ref: Regeneron | Image: Regeneron
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
